Solopharm is a Russian pharmaceutical company producing medicines, medical devices and dietary supplements.

Solopharm

Company history

July 2011

Start of the plant construction and laying of the foundation

March 2013

Completion of the construction and a start of an office work

June 2014

Launch of the 1st stage. The first series of infusion solutions are released

July 2015

Launch of the 2nd stage. Production of ophthalmic and nasal products in multidose form

April 2017

Launch of the 3rd stage - 10 new lines. The GMP certificate is received

April 2019

Solopharm becomes the fastest growing company for the second year in a row. «Platinum Ounce», the prestigious pharmaceutical award is received

May 2019

ISO 13485:2016 certificate for the export of medical devices is received

July 2020

Launch of the biotechnological developments’ laboratory

September 2020

Foundation for solid dosage forms plant is laid.
Solopharm is included in TOP-20 of pharmaceutical companies according to Forbes magazine

February 2021

Solopharm is in Top-10 of the most rapidly developing companies in retail segment by the end of 2020

July 2021

Solopharm receives the EAEU GMP Certificate

September 2021

Solopharm is ranked #16 on the Forbes’ 2021 list of best domestic drug manufacturers

January 2022

Solopharm launches a new manufacturing site for dietary supplements

April 2022

The plant for production of solid dosage forms is opened

June 2022

Confirmation of the Solopharm medical device quality management system to the ISO 13485: 2016 requirements

October 2022

Solopharm entered the TOP-10 in the «Made in St. Petersburg and Leningrad region» nomination, «Fontanka.ru - Recognition and Influence» award

December 2022

Solopharm is ranked #1 in terms of online sales growth rate (according to AlphaRM for 11M-2022)

April 2023

Launch of the 4th stage of the liquid dosage forms production. Increasing the manufacturing facilities of existing and new drugs production, incl. new release forms

April 2023

Launch of the 2nd stage of the dietary supplements plant. Production of dietary supplements in capsules

May 2023

Launch of the plant for design, production, and installation of clean rooms

June 2023

Groundbreaking of the Hormones plant (production of hormonal drugs)

October 2023

Solopharm entered again the TOP-10 in the «Made in St. Petersburg and Leningrad region» and «Employer of the year» nominations, «Fontanka.ru - Recognition and Influence» awards

March 2024

Launch of the ESS pharmaceutical warehouse

November 2024

Solopharm entered the TOP-10 finalists of the Award «Fontanka.ru: Recognition and Influence» in the nomination «Made in St. Petersburg and Leningrad Region»

TOP-10 manufacturers in the retail segment (AlphaRM, Jan. 2024)

16th place on the Forbes’ list as one the best Russian pharmaceutical companies (according to the Forbes rating, September 2021)

TOP-5 Russian manufacturers in terms of sales growth rates (according to the AlphaRM results, September 2022)

2-time winner of the «Platinum Ounce» pharmaceutical award. Category: «Dynamics of the Year»

№1 product on the osteoarthritis treatment market – Armaviscon

CPhI Awards nominee 2018. Category: «Excellence in Pharma: OTC»

TOP-6 of the fastest growing pharmaceutical companies: annual growth rate is 42% (AlphaRM, September 2022)

Angidak is the winner of the «Green Cross» award. «The drug of choice for the sore throat treatment», August 2022

Mestamidin-nasal is the most successful launch in 2021-2022 (according to the Ipsos results, September 2022)

The TOP-10 finalist of the Award «Fontanka.ru: Recognition and Influence» (2023) in the nominations «Made in St. Petersburg and Leningrad Region» and «Employer of the Year»

№1 in terms of growth rate of medical prescriptions (Ipsos, Q1 23-Q2 22)

Solopharm has received several awards at once at the Smartpharma® Awards 2023

IQ Provision project - №1 in the following nomination: «Informative and outreach project for pharmacy workers»

Gylan Comfort - №2 in the following nomination: «Artificial tear agent with hyaluronic acid in high concentration»

DeTriFerol - №2 in the nomination: «Vitamin D3 source for children from the first year of life»

LinAqua Soft - №3 in the nomination: «Nasal cavity care product»

Solopharm is included in the list of strategic enterprises

At the end of April 2023 Solopharm successfully launched two new production centers at its liquid dosage forms and food supplements plants

Solopharm has opened new doors - Matrix Wall (own production site for design, manufacture, and installation of clean rooms)

№1 in the ranking of manufacturers in the target market (According to Ipsos, March 2024, data on medical prescriptions, us + competitors)

TOP-3 in the ranking of domestic manufacturers (According to Ipsos, March 2024, data on medical prescriptions, production is localized in the Russian Federation)

Angidak® - the drug of choice for the «mountain» first aid kit for sore throat treatment («Pharmacology of Mountains» project)

TOP-10 manufacturers in the retail segment (According to AlphaRM, 3 months 2024)

TOP-10 leading companies in digital promotion (According to Ipsos, 2023 vs 2022)

6th place in the «Local manufacturing companies» nomination ("Bionika Media Innovations", publishing house, according to the leaders of the influence rating 2023)

№1 in the ophthalmic market segment in value terms (According to IQVIA and DSM Group, 2023, retail (Medical devices + Drugs)

№1 in the recommendations of ophthalmologists of Russia (According to Ipsos Prindex, Q1 2024)

№1 in the recommendations of otorhinolaryngologists of Russia (According to Ipsos Prindex, Q1 2024)

№5 in the recommendations of pediatricians of Russia (According to Ipsos Prindex, Q1 2024)

№8 in Russia by turnover in rubles and packs in the OTC segment (According to AlphaRM, in January-May 2024, dated in June 2024)

Olyfrin is №1 drug recommended by pediatricians and ENT doctors for the treatment and protection of nasal mucosa

Tramycent is №1 in the ENT doctors’ prescriptions for the treatment of complicated rhinitis

The-TOP 10 finalist of the Award «Fontanka.ru: Recognition and Influence» (2024) in the nomination «Made in St. Petersburg and Leningrad Region»

Photo 


 



TOP-10 manufacturers in the retail segment (AlphaRM, Jan. 2024)

More than 260 drugs in the Solopharm portfolio in various therapeutic areas

Photo 


 



TOP-10 manufacturers in the retail segment (AlphaRM, Jan. 2024)

More than 260 drugs in the Solopharm portfolio in various therapeutic areas

43 drugs and medical devices are currently in the registration phase 

192 drugs are currently in development

4 production sites equipped with modern equipment with a high degree of automation

The total area of all production sites is 35,000 m2 

Solopharm production is more than 28 production lines with a high level of automation

5.2 billion products a year produced by all Solopharm plants

Global presence

Карта мира
Belarus
Azerbaijan
Armenia
Vietnam
Georgia
Kyrgyzstan
Tajikistan
Kazakhstan
Cambodia
Uzbekistan
Morocco
Mongolia
Qatar
Kuwait

Solopharm today

Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is
Photo Solopharm is